Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2020 | Dara, len & dex for newly-diagnosed myeloma

Shaji Kumar • 11 Dec 2020
ASH 2020
Multiple Myeloma Antibodies Daratumumab Dexamethasone Lenalidomide
MAIA

Shaji Kumar, MD, Mayo Clinic, Rochester, MN presents the results of the Maia study (NCT02252172), a Phase III comparison of daratumumab, lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly-diagnosed multiple myeloma that are ineligible for autologous stem cell transplantation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Shaji Kumar

Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma 3:00
Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
Shaji Kumar • 17 Jun 2025
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma 2:37
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
Shaji Kumar • 17 Jun 2025
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T 1:57
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T
Shaji Kumar • 17 Jun 2025
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD 5:43
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD
Shaji Kumar • 17 Jun 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals